The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical ...

Amid current economic uncertainties, investing in defensive stocks appears as your best bet for stability, especially if a ...

GH Research's inhaled psychedelic therapy GH001 has shown promise in a mid-stage trial in treatment-resistant depression (TRD ...

Q4 2024 Earnings Call Transcript February 7, 2025 Operator: Ladies and gentlemen, thank you for standing by. Welcome to ...

Each of the RSU grants vests ratably in equal installments on the first, second, and third anniversaries of the grant date, subject to the recipient's continued service with the Company through the ...

Vanessa Kanu Kanu; Executive Vice President and Chief Financial Officer; Aptargroup Inc Ladies and gentlemen, thank you for standing by. Welcome to Aptar 2024 fourth quarter and annual results ...

Spravato has been approved since 2019 for TRD, with its label extended the following year as a rescue therapy for adults with major depressive disorder (MDD) who were at risk of self-harm or suicide.

Q Earnings: $3.4 billion (-17%) FY Revenues: $88.8 billion (+4%) FY Earnings: $14.1 billion (+6%) Comments: Innovative Medicin ...

Investing in dividend aristocrats can form the cornerstone of a reliable investment strategy, owing to their qualities like ...

The Food and Drug Administration (FDA) recently expanded approval for Spravato, an antidepressant nasal spray used to treat ...